We’re delighted to announce that our work on the APPEAL study has been nominated for a PMEA (Pharmaceutical Market Excellence Awards).
APPEAL is an ongoing study that explores the psychosocial burden of peanut allergy – we’ve been working for Aimmune Therapeutics alongside Brainsell and Acaster-Lloyd Consulting.
Our contribution has been varied, covering awareness work, strategy planning, advisory meetings, scientific writing, and creative study outputs.
It’s a very competitive category with some excellent entries, and we look forward to the awards ceremony (and finding out the winner!) in November.